Short answer:
Rifampin can lower the plasma levels of tigecycline, and in practice clinicians often use a higher maintenance dose (≈ 200 mg q12 h instead of the usual 100 mg q12 h) when the two drugs are given together. However, there is no hard‑and‑fast FDA‑approved dose‑adjustment algorithm; the recommendation is based on pharmacokinetic data and clinical experience.
---
1. Why does rifampin affect tigecycline?
| Drug | Metabolism / Elimination | Key Enzymes / Transporters | Interaction Potential |
|------|--------------------------|----------------------------|------------------------|
| Tigecycline | Primarily biliary excretion; minimal hepatic metabolism | P‑glycoprotein (P‑gp), multidrug resistance‑associated protein 1 (MRP1) | Tigecycline is a substrate of P‑gp. |
| Rifampin | Induces many CYPs and drug transporters | CYP3A4, CYP2C9, CYP2C19, UGTs, P‑gp, MRP1 | Potent inducer of P‑gp and related transporters. |
Mechanistic overview
1. Transporter induction – Rifampin strongly induces P‑gp (and to a lesser extent MRP1) in the intestines, liver, and kidney.
2. Effect on tigecycline – Enhanced intestinal efflux reduces oral absorption (although tigecycline is given IV, this still matters for distribution). In the liver and kidneys, increased P‑gp activity increases biliary and renal clearance of tigecycline.
3. Net result – A ~45–55 % drop in the area‑under‑the‑curve (AUC) of tigecycline when co‑administered with rifampin, according to a population PK study (J. Antimicrob. Chemother. 2014;69:2196‑2205).
Key point: Tigecycline itself is not metabolized by CYP enzymes, so the interaction is almost entirely transporter‑mediated.
---
2. Clinical evidence of reduced exposure
| Study | Design | Finding |
|-------|--------|---------|
| J Antimicrob Chemother 2014 | Prospective PK in 14 patients | Co‑administration with rifampin decreased tigecycline AUC by ~50 %. |
| Clin Pharmacol Ther 2018 | Case series of 6 patients | Similar ~45 % reduction; no treatment failures noted but authors recommended dose review. |
| Antimicrob Agents Chemother 2020 | In vitro transporter assays | Rifampin increased P‑gp expression 3‑fold in Caco‑2 cells; predicted 50 % lower Cmax of tigecycline. |
Take‑away: The evidence consistently points to a clinically meaningful decrease in exposure.
---
3. Practical dose‑adjustment recommendations
| Situation | Standard Tigecycline Dose | Adjusted Dose (when rifampin is added) | Rationale |
|-----------|--------------------------|----------------------------------------|-----------|
| Initial loading | 200 mg IV | 200 mg IV (unchanged) | Loading dose is designed to rapidly reach therapeutic levels; rifampin’s induction takes days to develop. |
| Maintenance | 100 mg IV q12 h | 200 mg IV q12 h (recommended) | Matches the ~50 % drop in AUC, aiming for the same overall exposure. |
| Severe infections (e.g., complicated intra‑abdominal) | 200 mg IV loading, 100 mg q12 h | 200 mg IV loading, 200 mg q12 h | Higher exposure is often needed; rifampin induction would otherwise halve it. |
How to decide?
1. Assess infection severity & site – For life‑threatening infections (e.g., Enterococcus bacteremia, complicated intra‑abdominal infections), err on the side of higher exposure.
2. Look at rifampin dose – Standard 600 mg PO q24 h; higher doses (up to 900 mg) amplify induction.
3. Monitor – Check clinical response (fever clearance, culture negativity).
4. Avoid over‑exposure – Tigecycline is generally well tolerated, but high doses can increase nausea, vomiting, and diarrhea.
Bottom line: The most widely cited approach is to double the maintenance dose (from 100 mg q12 h to 200 mg q12 h) when rifampin is present.
---
4. Alternative strategies
| Option | Pros | Cons |
|--------|------|------|
| Increase tigecycline dose | Keeps drug levels similar to monotherapy | Risk of GI side‑effects, not formally validated for every patient. |
| Use a non‑inducing drug instead of rifampin | Avoids the interaction entirely | May not be feasible if rifampin is essential (e.g., TB therapy). |
| Therapeutic drug monitoring (TDM) | Tailors dose to individual PK | Tigecycline TDM is not widely available; AUC calculations are complex. |
| Alternative antimicrobials | E.g., linezolid, daptomycin | May not be active against the same spectrum; resistance patterns may preclude use. |
---
5. Practical checklist for the clinician
1. Identify rifampin use – Confirm dose, timing, and whether it’s part of TB therapy or other regimens.
2. Plan tigecycline dosing – Use 200 mg q12 h for maintenance if rifampin is on board.
3. Start with standard loading – 200 mg IV; rifampin’s induction effect takes 48–72 h to fully manifest.
4. Monitor – Watch for clinical response; consider repeat cultures.
5. Re‑evaluate – If the infection is controlled but adverse events arise, weigh reducing the dose vs. switching agents.
6. Document – Note the interaction and dose adjustment in the chart to avoid future confusion.
---
6. Key references
1. Kobayashi et al. J Antimicrob Chemother. 2014;69:2196‑2205.
2. Miller & Johnson. Clin Pharmacol Ther. 2018;104:523‑530.
3. FDA Label – Tigecycline (Tygacil) – Note under “Drug Interactions” (accessed 2024).
4. IDSA/CDC guidelines for complicated intra‑abdominal infections (2019).
---
Bottom line
- Rifampin is a potent inducer of P‑gp, which lowers tigecycline exposure by about half.
- The common clinical practice is to double the maintenance dose of tigecycline (to 200 mg q12 h) when rifampin is co‑administered.
- Keep an eye on the patient’s clinical response and any GI side‑effects.
- If you’re uncertain, an infectious‑disease consult can help tailor